Topical Ruxolitinib for the Treatment of Alopecia Universalis
December 2015
in “
JAMA dermatology
”
TLDR Topical Ruxolitinib may safely treat severe hair loss.
The document discussed the potential of topical Ruxolitinib as a treatment for Alopecia Universalis, a severe form of alopecia areata. While oral Janus kinase (JAK) inhibitors had been effective in treating these conditions, they carried risks of serious adverse effects. The study suggested that using a topical form of Ruxolitinib could mitigate these risks, offering a safer alternative for patients.